What a growth hormone secretagogue actually does
Ipamorelin and CJC-1295 do not contain growth hormone. They instruct the pituitary to release more of the hormone it already makes. Injected GH puts a fixed quantity into the blood regardless of what the body would have done on its own; a secretagogue asks a gland to work harder, and the gland answers within limits it sets for itself. That single difference determines almost everything else about how this class behaves.
The first consequence is a ceiling. GH output is bounded by how much hormone the somatotrophs hold, by hypothalamic somatostatin tone, and by IGF-1 travelling back to shut the loop down. Push harder and the loop pushes back. Exogenous GH has no such governor, which is why it can drive IGF-1 into acromegalic ranges and why it produces both the strongest and the worst effects of anything in this space.
So a secretagogue is a smaller intervention with a shorter reach. It exaggerates a normal signal rather than overriding it. Whether that is a virtue depends on the goal. For a defined problem like HIV-associated visceral fat accumulation, a GHRH analogue is approved and demonstrably works. For reversing ageing, nothing in the human record supports it, and the more powerful version of the same intervention has already failed that test.
Two receptors, two drug classes, one loose label
The phrase growth hormone secretagogue covers two mechanisms that share an output and very little else. GHRH analogues, including sermorelin, tesamorelin and CJC-1295, bind the GHRH receptor on the somatotroph, the same receptor the hypothalamus uses. GHS-R1a agonists, including ipamorelin, the older growth hormone releasing peptides and the oral non-peptide MK-677, bind the ghrelin receptor instead, amplifying release partly by suppressing somatostatin tone.
Ipamorelin's claim to attention is selectivity. In its original 1998 characterisation it released GH in rats and swine with potency comparable to GHRP-6, but left ACTH and cortisol unmoved at exposures far above the threshold for GH release. That distinguishes it from GHRP-2, GHRP-6 and hexarelin, which carry measurable cortisol and prolactin cross-stimulation. Selectivity is the honest selling point, and it is preclinical pharmacology rather than a clinical outcome.
Because the two receptors pull different levers, combining them yields more GH than adding the two effects together. Human work going back to 1990 showed that a GHRP given with GHRH released more hormone than either agent alone. That synergy is the entire rationale for the CJC-1295 plus ipamorelin pairing that dominates the grey market. It is also where the evidence stops: the combination has never been tested against any clinical endpoint in a controlled human trial.
The DAC distinction: two molecules sharing one name
CJC-1295 as it was actually developed is a tetrasubstituted analogue of the first 29 amino acids of GHRH, carrying a linker that binds covalently to circulating albumin. That drug affinity complex is the whole invention. It converts a peptide with a few minutes of half-life into one measured in days, which is why a single injection in the published phase 1 work kept IGF-1 elevated for more than a week.
What circulates under the same name outside clinical development is usually not that molecule. CJC-1295 without DAC is modified GRF(1-29): the same stabilising substitutions, no albumin linker, clearance on the order of half an hour. The two share a name and a backbone and behave nothing alike. A study of one says almost nothing about the other, and listings routinely fail to distinguish them, which makes much of the discussion of this compound incoherent before it starts.
The distinction matters most for the shape of the signal. The short version produces a discrete pulse and clears. The DAC version holds GHRH receptor occupancy elevated continuously for days, which is not what the receptor evolved for. The phase 1 data reported that pulsatile secretion was preserved while mean GH concentrations and IGF-1 rose, a more reassuring result than the pharmacology would predict. It comes from small, short studies in healthy volunteers, and no long-term human data extend it.
Why IGF-1 feedback sets the ceiling
GH acts on the liver to produce IGF-1, and IGF-1 travels back to the hypothalamus and pituitary to raise somatostatin tone and blunt further GH release. That loop is the reason a secretagogue cannot simply be pushed harder for more effect. As IGF-1 rises, the same stimulus buys progressively less hormone. The system is built to defend a set point rather than to maximise output.
The ceiling is not absolute. Tesamorelin at its labelled dose of 2 mg once daily subcutaneously raises IGF-1 substantially and pushes a minority of patients above the reference range for their age, which is why the label calls for IGF-1 monitoring. But it is a different shape of exposure from injected GH, where the dose sets the level and the feedback loop has no vote.
The other hard limit is the gland itself. A secretagogue needs somatotrophs capable of responding. In organic growth hormone deficiency caused by pituitary surgery, a tumour or cranial radiation, there is nothing left to stimulate. The population with the least ambiguous need for growth hormone is the one this class cannot serve, while in healthy adults the reserve is intact, the response is real, and the potential gain is smallest.
Pulsatility, and what continuous stimulation does to it
GH is not secreted at a steady level. It arrives in bursts, the largest during slow-wave sleep, with near-undetectable troughs between them. The troughs are part of the message: hepatic gene expression in rodents tracks the pattern of exposure rather than the total amount, which is how the same hormone produces different liver phenotypes in males and females.
Continuous stimulation of a receptor built for intermittent signals is the standard recipe for desensitisation. Sustained GHRH receptor occupancy attenuates the somatotroph response over time, and the same applies to sustained GHS-R1a agonism. The compounds engineered to last longest therefore carry the clearest theoretical liability, and the reported preservation of pulsatility with the albumin-bound construct is worth holding loosely rather than treating as settled.
What would show up first is a shrinking IGF-1 response, not a dramatic collapse. Nothing published follows a secretagogue in healthy adults at a fixed exposure long enough to say where that curve flattens. The two-year MK-677 trial is the closest approximation, and it reported IGF-1 sustained at young-adult levels throughout. That is evidence against rapid tachyphylaxis for one compound at one exposure, not evidence about the class.
What has actually been measured in humans
The only GH secretagogue with a current FDA approval is tesamorelin, a GHRH analogue approved in 2010 to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Two 26-week randomised trials showed visceral adipose tissue falling by roughly a tenth to a sixth against placebo, with triglycerides improving alongside. The extension phases showed the fat returning once treatment stopped. The effect is maintained by continued treatment, not installed by it.
A later randomised trial in people with HIV and fatty liver disease reported reduced hepatic fat over 12 months of tesamorelin. That is a genuine result in a defined population, and it has not been extended to fatty liver in the general population, where the drug is neither approved nor tested at scale.
The most informative trial in otherwise healthy people is a two-year randomised study of the oral secretagogue MK-677 in older adults. It did what it was designed to do: GH and IGF-1 rose to levels typical of young adults and stayed there for the duration. Fat-free mass increased by roughly 1.6 kg over placebo. Strength did not improve. Neither did function. Fasting glucose and insulin resistance rose. That trial is the clearest answer available to the question of what restoring a young GH profile in an older body actually buys.
The negative record is longer than the positive one. A 12-month randomised trial of MK-677 in Alzheimer's disease found no slowing of cognitive or functional decline despite sustained IGF-1 elevation, and the compound was never approved for anything. Ipamorelin entered clinical development and reached approval for no indication. CJC-1295 has published phase 1 pharmacology and no completed phase 3 programme. Sermorelin held a US approval and was withdrawn from the market in 2008 for commercial reasons, leaving a compound with a real regulatory history and no approved product behind it.
Where the anti-ageing framing outruns the evidence
The framing traces back to a 1990 study of twelve men over 60 given growth hormone for six months, in which lean body mass rose by roughly nine percent and fat mass fell by roughly fourteen percent. Body composition was all it measured: no strength tests, no functional outcomes, no long-term follow-up, and no claim in the paper that ageing had been reversed. Three and a half decades of marketing rest on a twelve-person body-composition study.
The work that followed is far less flattering. A 2007 systematic review pooled the controlled trials of growth hormone in healthy older adults and found around two kilograms of lean mass gained and a similar quantity of fat lost, with no improvement in strength or in any functional measure, and higher rates of soft tissue oedema, joint pain, carpal tunnel syndrome, gynaecomastia and impaired fasting glucose. That is the realistic ceiling for exogenous GH, which is the stronger intervention.
A secretagogue cannot reasonably be expected to exceed it. It acts through the same hormone, at lower and feedback-limited exposures, in people whose axis is already working. The two-year MK-677 trial landed where the GH literature predicted: mass without function. Any claim that a secretagogue restores youthful performance is claiming an outcome the more powerful version of the same intervention has repeatedly failed to produce.
The side effects follow directly from the mechanism
Growth hormone opposes insulin. Sustained elevation raises fasting glucose and worsens insulin sensitivity, a consistent finding across GH and secretagogue trials rather than an idiosyncratic reaction in a few people. In the two-year MK-677 study it was the principal safety signal, and in anyone with prediabetes or established diabetes it is the most predictable problem with the class.
Fluid retention, joint pain and carpal tunnel symptoms are dose-related GH effects and appear in the secretagogue literature too, in proportion to how much hormone is released. GHS-R1a agonists add an effect of their own: as ghrelin mimetics they increase appetite and food intake. That is exactly the effect wanted in cachexia and exactly the effect not wanted by someone taking them in pursuit of fat loss.
The IGF-1 question deserves to be stated precisely. Higher circulating IGF-1, even within the normal range, is associated in pooled prospective cohort data with modestly higher risk of several cancers, breast and prostate among them. An observational association in people whose IGF-1 differs naturally is not evidence that raising IGF-1 pharmacologically for months carries the same risk, and no trial in this class has been large or long enough to test it. It is an open question, neither a settled hazard nor a non-issue.
Regulatory status, stated plainly
Tesamorelin is FDA-approved for one indication and no others. Sermorelin was approved and is no longer marketed in the United States as an approved product, reaching patients now only through compounding. Ipamorelin, CJC-1295 and MK-677 have no US approval for any indication, and describing them as medications rather than unapproved drugs is a category error.
Compounding is where most of the confusion lives. In 2023 the FDA placed ipamorelin and CJC-1295 in the category of nominated bulk drug substances that raise significant safety concerns, which means neither may lawfully be compounded from bulk substance under the 503A pathway. A clinic offering them is not dispensing an approved drug, and a compounded preparation has not been evaluated by the FDA for safety, efficacy or manufacturing quality.
Every compound discussed here is prohibited in sport at all times. The WADA list names growth hormone releasing factors and their analogues, including sermorelin, tesamorelin and CJC-1295, alongside secretagogues including ipamorelin and MK-677. Because they raise endogenous hormone, the isoform test designed to catch injected recombinant GH will not flag them. The compounds themselves are detectable in urine, and the biomarker panel based on IGF-1 and a procollagen fragment responds to elevated GH whatever its source.
How to read a claim about these compounds
Three questions separate signal from noise. Which molecule is it exactly, with DAC or without, ipamorelin or one of the less selective GHRPs? What was the endpoint, a hormone concentration, an imaging measure, or something a person could feel or do? And in whom, given that HIV-associated lipodystrophy and healthy middle-aged adults are different populations whose results do not transfer?
The honest summary is narrow. GH secretagogues reliably raise GH and IGF-1 in people with an intact pituitary; that is not in dispute. One of them, in one indication, reduces visceral fat by enough to have earned an approval. Beyond that, the class has produced changes in body composition without matching changes in strength, function or any hard clinical outcome, and the trials that looked hardest for those outcomes are the ones that came back negative.
That is not the same as saying nothing happens. It is saying that the measured effects are the modest ones, the effects being sold are the unmeasured ones, and the distance between a hormone level and a life outcome is precisely where the marketing case for this class is built.